Health
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy – News-Medical.net
Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avacta’s neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future globa…
-
Business24 hours agoWhy Amotiv, Breville, Life360, and Woodside shares are tumbling today
-
Noosa News23 hours agoNicole Kidman Is Back in Wellness Guru Mode: ‘Nine Perfect Strangers’ Season Two Will Hit Your Streaming Queue in May
-
Noosa News22 hours agoDevastating update in search for missing Queensland mother Tayla Spies as police find human remains near her ute
-
Noosa News23 hours agoDingoes bite 3 women on K’gari